Oncotarget

Research Papers:

Genetic variants of CHRNA5-A3 and CHRNB3-A6 predict survival of patients with advanced non-small cell lung cancer

Yang Wang, Xiaonu Peng, Lijun Zhu, Likuan Hu and Yipeng Song _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:26436-26443. https://doi.org/10.18632/oncotarget.8510

Metrics: PDF 1169 views  |   HTML 1968 views  |   ?  


Abstract

Yang Wang1,*, Xiaonu Peng1,*, Lijun Zhu2,*, Likuan Hu3, Yipeng Song1

1Department of Radiation Oncology, Yantai Yuhuangding Hospital, Yantai, Shandong, China

2Department of Oral and Maxillofacial Surgery, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China

3Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong, China

*Co-first authors, these authors contributed equally to this work

Correspondence to:

Yipeng Song, email: [email protected]

Keywords: CHRNA5-A3, CHRNB3-A6, survival, nicotinic acetylcholine receptors, lung cancer

Received: February 02, 2016     Accepted: March 10, 2016     Published: March 30, 2016

ABSTRACT

Nicotinic acetylcholine receptors (nAChRs) play a key role in carcinogenesis and progression of lung cancer; and polymorphisms in CHRNA5-A3 and CHRNB3-A6, two gene clusters encoding nAChR subunits, have been associated with lung cancer risk. In this study, we investigated whether variants in the two gene clusters were associated with prognosis of advanced non-small cell lung cancer (NSCLC). A total of 165 stage IIIB–IV NSCLC patients were enrolled in this study. Three polymorphisms (rs667282 and rs3743073 in CHRNA5-A3 and rs13280604 in CHRNB3-A6) were genotyped using the TaqMan method. Overall survival (OS) was estimated using the log-rank test and the Cox models. Our results showed that patients with CHRNA5-A3 rs667282 TT or TC genotypes had a significantly shorter OS than those carrying the CC genotype (Log-rank, P = 0.043). Furthermore, multivariate Cox regression analysis showed that rs667282 TT/TC genotypes are significantly associated with increased risk of overall deaths (adjusted hazard ratio, 1.7; 95% CI, 1.1–2.7). However, the similar results were not observed for other two polymorphisms. Furthermore, no evident association was found between these variants and clinicopathologic features of advanced NSCLC. Our present study suggested that rs667282 in CHRNA5-A3 may modify the prognosis of patients with advanced NSCLC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8510